Ollin Biosciences Signs a ~$440M Licensing Agreement with VelaVigo Bio for VBS-102
Shots:
- VelaVigo Bio has granted Ollin Biosciences an exclusive license to develop, manufacture & commercialize VBS-102 worldwide, except Greater China, where VelaVigo will maintain its rights
- As per the deal, VelaVigo will receive an upfront payment along with development, regulatory, & commercial milestones in cash & equity, making an aggregate of ~$440M, plus tiered royalties based on sales
- Additionally, VelaVigo to advance its fully owned lead FIC/BIC bispecific ADC into a US trial in 2025, & will showcase 5 additional FIC/BIC molecule data at future conferences to explore global partnership opportunities
Ref: Prnewswire | Image: VelaVigo
Related News:- BigHat Biosciences Collaborates with Eli Lilly to Advance AI-Driven Antibody Therapeutics
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
